Sequoia Financial Advisors LLC Sells 1,000 Shares of Thermo Fisher Scientific Inc. $TMO

Sequoia Financial Advisors LLC cut its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,810 shares of the medical research company’s stock after selling 1,000 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Thermo Fisher Scientific were worth $7,425,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Brighton Jones LLC raised its holdings in Thermo Fisher Scientific by 28.9% in the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock valued at $2,293,000 after acquiring an additional 988 shares during the period. Revolve Wealth Partners LLC grew its position in shares of Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after purchasing an additional 20 shares during the last quarter. Darwin Wealth Management LLC bought a new position in shares of Thermo Fisher Scientific during the second quarter worth approximately $170,000. Raymond James Financial Inc. lifted its holdings in Thermo Fisher Scientific by 7.4% during the 2nd quarter. Raymond James Financial Inc. now owns 778,822 shares of the medical research company’s stock worth $315,781,000 after purchasing an additional 53,542 shares during the last quarter. Finally, California State Teachers Retirement System boosted its stake in Thermo Fisher Scientific by 0.4% in the 2nd quarter. California State Teachers Retirement System now owns 602,031 shares of the medical research company’s stock valued at $244,099,000 after purchasing an additional 2,262 shares during the period. Institutional investors own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on TMO. Wells Fargo & Company lowered their price objective on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Jefferies Financial Group reiterated a “buy” rating and issued a $630.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, July 23rd. KeyCorp reissued an “overweight” rating on shares of Thermo Fisher Scientific in a report on Tuesday, May 26th. Royal Bank Of Canada raised their target price on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a “sector perform” rating in a report on Friday, July 24th. Finally, Sanford C. Bernstein started coverage on Thermo Fisher Scientific in a research note on Friday, June 26th. They issued a “market perform” rating and a $520.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $619.41.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 4,608 shares of the company’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $586.12, for a total transaction of $2,700,840.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa P. Britt sold 5,850 shares of Thermo Fisher Scientific stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $580.00, for a total value of $3,393,000.00. Following the completion of the transaction, the vice president owned 14,784 shares in the company, valued at approximately $8,574,720. This represents a 28.35% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 52,053 shares of company stock worth $30,643,589 over the last quarter. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Price Performance

TMO stock opened at $588.17 on Friday. The company’s 50-day moving average price is $529.37 and its two-hundred day moving average price is $509.58. The firm has a market cap of $217.47 billion, a P/E ratio of 31.64, a P/E/G ratio of 2.39 and a beta of 0.85. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific Inc. has a 12 month low of $435.27 and a 12 month high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. During the same quarter in the prior year, the firm posted $4.28 EPS. The firm’s quarterly revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be paid a $0.47 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.11%.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.